Cowen and Company’s Bristol-Myers Squibb BMY Stock Holding History

Cowen and Company’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17,500	Closed	-$11K	–	675
2022 Q2	$11K	Buy	+17,500	New	+$1.33M	﹤0.01%	464
2021 Q4	–	Sell	-35,000	Closed	-$60K	–	652
2021 Q3	$60K	Buy	+35,000	New	+$2.3M	﹤0.01%	369
2020 Q1	–	Sell	-111,100	Closed	-$2K	–	428
2019 Q4	$2K	Buy	+111,100	New	+$6.36M	﹤0.01%	430

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Cowen and Company's BMY Position: Q1 2023 in Review

Cowen and Company sold out of Bristol-Myers Squibb (BMY) in Q1 2023, closing a stake of 5,349 shares — an estimated $385K sold.

Cowen and Company first reported a position in BMY in Q4 2019 and held it in 7 quarters. The position peaked at $2.15M in Q3 2021. 2,541 funds tracked by Wall St. Rank hold BMY as of Q1 2023.

Cowen and Company reported no remaining Bristol-Myers Squibb position as of Q1 2023 after selling out during the quarter.
Cowen and Company sold 5,349 Bristol-Myers Squibb shares in Q1 2023, an estimated $385K.
Cowen and Company first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 7 quarters.
Cowen and Company's Bristol-Myers Squibb position peaked at $2.15M in Q3 2021.
2,541 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.